Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

WINDWARD BIO GROUP AG

CIK 2145089Updated Nov 19, 2026

WWB price & chart

Provider market data

Loading TradingView…

NASDAQ:WWB on TradingView ↗

TradingView · Data may be delayed

About the company

We are a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. We estimate these diseases collectively represent a $60 billion peak market opportunity for biologic therapies, as we believe the majority of patients eligible to receive biologic treatment for these diseases remain untreated. Our product candidates can potentially address this significant unmet need, allow for treatment of a broader population of patients, improve efficacy, and improve dosing convenience and adherence to treatment. We estimate that these diseases collectively affect more than 100 million people in the United States, EU5 (France, Germany, Italy, Spain, and the United Kingdom), and Japan and more than 8 million are eligible for biologics treatment.

424B4 · 2026-11-16 · 0001193125-26-461203

Company description from the cited filing.

In the news

Recent filings

  1. 4 filing

    4 · 2026-11-18 · 0000947871-26-001039

  2. 4 filing

    4 · 2026-11-18 · 0000947871-26-001038

  3. 4 filing

    4 · 2026-11-18 · 0001361712-26-000011

  4. 4 filing

    4 · 2026-11-16 · 0001361712-26-000009

  5. 4 filing

    4 · 2026-11-16 · 0001572451-26-000010

Show 5 more recent filings
  1. 4 filing

    4 · 2026-11-16 · 0001776393-26-000007

  2. 4 filing

    4 · 2026-11-16 · 0001677141-26-000011

  3. 4 filing

    4 · 2026-11-16 · 0001618945-26-000007

  4. 6-K filing

    6-K · 2026-11-16 · 0001193125-26-463922

  5. 424B4 filing

    424B4 · 2026-11-16 · 0001193125-26-461203

Offerings

Registration 333-299608

424B4 · 2026-11-16 · 0001193125-26-461203

Terms from the governing filing for this registration; not a claim that the offering is open today.

Gross proceeds
174999989.0
Net proceeds
162749989.77
Deal price
17.0
Shares
10294117
Offering price
$17.00
Ticker
WWB

Underwriters: Jefferies LLC, TD Securities LLC, Piper Sandler & Co., UBS Securities LLC

Filing attachments

d111653dex107.htm · F-1/A · 2026-11-09

Exhibit 10.7 COMMON SHARE AND PRE-FUNDED WARRANT PURCHASE AGREEMENT T HIS C OMMON S HARE AND P RE -F UNDED W ARRANT P URCHASE A GREEMENT ( THIS “A GREEMENT ”) is entered into as of November 9, 2026 (the “Effective Date”), by and between Sanofi Foreign Participations B.V., a company incorporated under the laws of the Netherlands (the “Investor”) and Windward Bio Group AG, a Swiss corporation (Aktiengesellschaft) organized under the laws of Switzerland, with registered office in Basel, Switzerla…

F-1/A · 2026-11-09 · 0001193125-26-452536

Read attachment ↗
d111653dex42.htm · F-1/A · 2026-11-09

Exhibit 4.2 FORM OF PRE-FUNDED WARRANT THE SECURITIES REPRESENTED BY THIS WARRANT AND THE SECURITIES ISSUABLE UPON ITS EXERCISE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN AVAILABLE EXEMPTION FROM REGISTRATION. WINDWARD BIO GROUP AG PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Number of Warrant Shares: [•…

F-1/A · 2026-11-09 · 0001193125-26-452536

Read attachment ↗
d111653dex41.htm · F-1 · 2026-10-23

Exhibit 4.1 Form of Series B Warrant Agreement dated as of [date] by and among Windward Bio Group AG (the Company) Aeschenplatz 6 4052 Basel Switzerland and [name] (the Warrant Holder) [address] (the Company and the Warrant Holder each a Party and together the Parties) Whereas 3 1. Definitions and Interpretation …

F-1 · 2026-10-23 · 0001193125-26-430315

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.